Target: SSTR2

Indicant: Neuroendocrine tumor

MOA & Molecule Type: Peptide Receptor Radionuclide Therapy

Development stage: R&D

Summary: SSTR2 (Somatostatin Receptor 2) is a membrane protein present in the cell membrane that recognizes Somatostatin (peptide hormone) as a signal and regulates the secretion of hormones. SSTR2 is a target for neuroendocrine tumor treatments, and a representative treatment is Lutathera, a PRRT-based neuroendocrine tumor treatment. We designed a treatment with a Pro-Drug structure and secured a peptide that can bind to FAP-α with high expression around cancer cells. After binding to FAP-α, the peptide was isolated from the treatment and was developed to act only on cancer cells expressing SSTR2. Our company substance can lower toxicity to normal cells and increase specificity to cancer cells compared to Lutathera.